A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on…

Shoreline Biosciences to Present Two Posters on Ink Cell Platform At 19th Meeting of The Society for Natural Immunity (NK2022)

SAN DIEGO, May 10, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent…

Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells

SAN DIEGO, April 12, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent…